Methylone for the Treatment for PTSD: Initial Results From an Open-Label Study (IMPACT-1)

被引：0
|
作者：
Jones, Amanda [1 ]
Warner-Schmidt, Jennifer [1 ]
Stogniew, Martin [1 ]
Mandell, Blake [1 ]
Kwak, Hannah [1 ]
Miller, Paul W. [1 ]
Ching, Terence H. W. [1 ]
Averill, Lynnette [1 ]
Kelmendi, Benjamin [1 ]
机构：
[1] Transcend Therapeut, New York, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2023年 / 48卷
关键词：
Methylone; PTSD; Transcend Therapeutics; Human; Clinical Trial;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
P26
引用
收藏
页码：77 / 78
页数：2
相关论文
共 50 条
  • [1] TSND-201 (METHYLONE) FOR THE TREATMENT OF PTSD: IMPROVEMENTS ACROSS EACH CAPS-5 CLUSTER AND ANXIETY SYMPTOMS FROM THE OPEN-LABEL PORTION OF THE IMPACT-1 STUDY
    Jones, Amanda
    Warner-Schmidt, Jennifer
    Stogniew, Martin
    Mandell, Blake
    Kwak, Hannah
    Miller, Paul
    Jordan, Iain
    Ching, Terence
    Kelmendi, Benjamin
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 : 487 - 487
  • [2] A brief treatment for veterans with PTSD: an open-label case-series study
    Kindt, Merel
    Soeter, Marieke
    FRONTIERS IN PSYCHIATRY, 2023, 14
  • [3] Low dose oral ketamine treatment on post-traumatic stress disorder (PTSD) (OKTOP): An open-label pilot study
    Quigley, Bonnie L.
    Can, Adem T.
    Dutton, Megan
    Gallay, Cyrana C.
    Forsyth, Grace
    Jones, Monique
    Randall, Fiona
    Wilson, Trish
    Lagopoulos, Jim
    Hermens, Daniel F.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2025, 93 : 17 - 18
  • [4] AN OPEN-LABEL PILOT TRIAL OF INTEGRATED EXPOSURE-BASED TREATMENT FOR PTSD AND OPIOID USE DISORDER
    Saraiya, Tanya
    Singal, Sonali
    Johal, Priya
    Daruvala, Tamina
    Hien, Denise
    Back, Sudie
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 : 259 - 259
  • [5] Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
    Justice, Jamie N.
    Nambiar, Anoop M.
    Tchkonia, Tamar
    LeBrasseur, Nathan K.
    Pascual, Rodolfo
    Hashmi, Shahrukh K.
    Prata, Larissa
    Masternak, Michal M.
    Kritchevsky, Stephen B.
    Musi, Nicolas
    Kirkland, James L.
    EBIOMEDICINE, 2019, 40 : 554 - 563
  • [6] Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study
    Haab, Francois
    Corcos, Jacques
    Siami, Paul
    Glavind, Karin
    Dwyer, Peter
    Steel, Michael
    Kawakami, Fernando
    Lheritier, Karine
    Steers, William D.
    BJU INTERNATIONAL, 2006, 98 (05) : 1025 - 1032
  • [7] Treatment of mucocutaneous manifestations in Behcet's disease with anakinra: a pilot open-label study
    Grayson, Peter C.
    Yazici, Yusuf
    Merideth, Melissa
    Sen, H. Nida
    Davis, Michael
    Novakovich, Elaine
    Joyal, Elizabeth
    Goldbach-Mansky, Raphaela
    Sibley, Cailin H.
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [8] Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata
    Eisinger, Steve H.
    Fiscella, Julietta
    Bonfiglio, Thomas
    Meldrum, Sean
    Fiscella, Kevin
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2009, 146 (02) : 215 - 218
  • [9] Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open-label, dose-finding, phase 2 trial
    Vaitkevicius, Henrikas
    Ramsay, R. Eugene
    Swisher, Christa B.
    Husain, Aatif M.
    Aimetti, Alex
    Gasior, Maciej
    EPILEPSIA, 2022, 63 (09) : 2381 - 2391
  • [10] Nerve Growth Factor for the Treatment of Spinocerebellar Ataxia Type 3: An Open-label Study
    Tan, Song
    Wang, Rui-Hao
    Niu, Hui-Xia
    Shi, Chang-He
    Mao, Cheng-Yuan
    Zhang, Rui
    Song, Bo
    Sun, Shi-Lei
    Liu, Xin-Jing
    Hou, Hai-Man
    Liu, Yu-Tao
    Gao, Yuan
    Fang, Hui
    Kong, Xiang-Dong
    Xu, Yu-Ming
    CHINESE MEDICAL JOURNAL, 2015, 128 (03) : 291 - 294
12345